Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07197944 · ClinicalTrials.gov registry record · Phase 3

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

A Phase 3 study of Short Bowel Syndrome, sponsored by Zealand Pharma.

Recruiting
Registry status
Phase 3
Development phase
90
Enrollment target
17
Study locations

NCT07197944 is a Phase 3 study of Short Bowel Syndrome that is actively recruiting participants, run by Zealand Pharma. The registered enrollment target is 90 participants, below the 180-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (50% lower). The trial reports 17 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07197944, a Phase 3 study of Short Bowel Syndrome, is actively recruiting participants, sponsored by Zealand Pharma.

RECRUITING
Registry status
Phase 3
Development phase
90 participants
Enrollment target
17
Study locations

Study Summary

The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.

Conditions Studied

Short Bowel Syndrome

Interventions

  • OTHER Placebo
  • DRUG Glepaglutide

Study Locations (17)

Other

  • Rigshospitalet-Blegdamsvej 9 - Copenhagen
  • AP-HP - Hôpital Beaujon - Clichy
  • Charité - Universitätsmedizin Berlin - Berlin
  • Universitätsklinikum Bonn - Bonn
  • Oslo Universitetssykehus HF, Ullevål - Oslo
  • Sahlgrenska Universitets sjukhuset - Gothenburg
  • Karolinska Universitetssjukhuset Solna - Solna

Madrid

  • Hospital General Universitario Gregorio Marañon - Madrid
  • Hospital Universitario 12 de Octubre - Madrid

Missouri

  • Washington University Center for Advanced Medicine - St Louis

Vienna

  • Universitätsklinikum AKH Wien - Vienna

Mecklenburg-Vorpommern

  • Universitätsmedizin Rostock - Rostock

Saxony

  • Eugastro Klinische Studien GmbH - Leipzig

Lazio

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - PPDS - Rome

Gelderland

  • Radboud Universitair Medisch Centrum - Nijmegen

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2026-02-11
Est. Completion 2032-02-28
Phase Phase 3

Sponsor

Zealand Pharma

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07197944

The ClinicalTrials.gov registry entry for NCT07197944 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (50% lower). The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07197944 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Other, Madrid, Missouri.

Frequently Asked Questions

What is clinical trial NCT07197944 about?

NCT07197944 is a clinical study titled "Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS". The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848...

What is the current status of trial NCT07197944?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2026-02-11. Estimated completion is 2032-02-28.

What conditions does trial NCT07197944 study?

This clinical trial studies the following conditions: Short Bowel Syndrome.

What interventions are being tested in trial NCT07197944?

The interventions under investigation include: Placebo (OTHER), Glepaglutide (DRUG).

Who is sponsoring clinical trial NCT07197944?

This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07197944 being conducted?

This trial has 17 study locations across Missouri, Vienna, Mecklenburg-Vorpommern, Saxony, Lazio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Short Bowel Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Short Bowel Syndrome

All registered trials for this condition

Missouri

All trials with a study site in Missouri

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.